Dosage form
capsules
Composition
ribavirin 200 mg.

Excipients: lactose (milk sugar), silicon dioxide colloidal (Aerosil), magnesium stearate.
Pharmacological action
Ribavirin penetrates the virus-infected cells and quickly fosfauriliruetsa adenocarcinoid in intracellular ribavirin mono-, di - and triphosphate. These metabolites, especially ribavirin triphosphate, have a pronounced antiviral activity. The mechanism of action of ribavirin are not very clear. However, it is known that ribavirin inhibits the inosine monophosphate dehydrogenase (IMP), this effect leads to a strong decrease in the level of intracellular guanosine triphosphate (GTP), which in turn is accompanied by suppression of synthesis of viral RNA and the virus specific proteins. Ribavirin inhibits the replication of new virions, thereby reducing the viral load. Ribavirin selectively inhibits synthesis of viral RNA, not inhibiting RNA synthesis in normally functioning cells. Ribavirin is effective against many DNA and RNA viruses.The most sensitive for the ribavirin DNA viruses are: herpes virus Simpleх, poks virus, the virus of Marek?s illness. Insensitive to for the ribavirin DNA viruses are: Varicella Zoster, pseudorabies, cow smallpox. The most sensitive for the ribavirin RNA viruses are: influenza A, B, paramyxovirus (parainfluenza, epidemic parоtite, Nucasl?s illness), reoviruses, RNA tumoral viruses. Insensitive to for the ribavirin RNA viruses include: enteroviruses, rhinovirus, Semlicy Forest. Ribavirin has activity against the hepatitis C virus (HCV). The mechanism of action of ribavirin against HCV are not completely understood. It is assumed that accumulated as phosphorylation, ribavirin triphosphate is a competitive inhibits the formation of guanosine triphosphate, thereby reducing the synthesis of viral RNA. It is also believed that the mechanism of synergistic action of ribavirin and alpha interferon against HCV is due to increased phosphorylation of ribavirin with interferon.

Testimony
Chronic hepatitis C (in combination with interferon Alfa-2B or peginterferon Alfa-2B): patients not previously treated with interferon Alfa-2B or peginterferon alpha-2B; when aggravation after a course of monotherapy with interferon Alfa-2B or peginterferon alpha-2B; in patients unresponsive to monotherapy with interferon Alfa-2B or peginterferon alpha-2B.
Contraindications
Hypersensitivity, pregnancy, lactation, chronic heart failure IIB-III of St, myocardial infarction, renal failure (creatinine clearance less than 50 ml/min), severe anemia, hepatic failure, decompensated cirrhosis, autoimmune diseases (including autoimmune hepatitis), incurable thyroid disease, severe depression with suicidal intentions, children and youth age (up to 18 years).